8-K: Sotera Health Reports Strong Q3 2025 Results, Raises Outlook

Sotera Health Company announced robust third-quarter and year-to-date 2025 financial results, driven by strong revenue and Adjusted EBITDA growth, leading to an increased full-year Adjusted EBITDA and Adjusted EPS outlook.

Summary

• Third-quarter 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis, compared to Q3 2024.
• Third-quarter 2025 net income was $48 million, or $0.17 per diluted share, a significant increase from $17 million, or $0.06 per diluted share, in Q3 2024.
• Third-quarter 2025 Adjusted EBITDA increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024.
• Third-quarter 2025 Adjusted EPS increased by $0.09 to $0.26, compared to $0.17 in Q3 2024.
• For the first nine months of 2025, net revenues increased 6.2% to $860 million, or 6.2% on a constant currency basis, compared to the same period in 2024.
• Year-to-date 2025 net income was $43 million, or $0.15 per diluted share, which includes previously disclosed settlements of approximately $31 million and pending settlements of $34 million related to ethylene oxide (EO) claims.
• Year-to-date 2025 Adjusted EBITDA increased 10.4% to $437 million, or 10.6% on a constant currency basis, compared to the same period last year.
• Year-to-date 2025 Adjusted EPS increased by $0.11 to $0.60, compared to $0.49 in the first nine months of 2024.
• The company is raising its 2025 Adjusted EBITDA growth range to 6.75% 7.75% and its Adjusted EPS range to $0.81 $0.86.
• The 2025 net revenues outlook range of 4.5% 6.0% on a constant currency basis is reaffirmed.
• The Net Leverage Ratio improved to 3.3x as of September 30, 2025, from 3.7x as of December 31, 2024, moving closer to the long-term goal of 2.0x to 3.0x.
• Capital expenditures outlook for 2025 was revised down to $125 million to $135 million from a previous outlook of $170 million to $180 million.

Sentiment

Score: 8

Explanation: The company reported strong financial performance across key metrics, raised its full-year Adjusted EBITDA and Adjusted EPS outlook, and significantly improved its leverage ratio, indicating robust operational execution and financial health despite some segment-specific revenue declines.

Positives

• Q3 2025 net revenues increased 9.1% to $311 million (8.0% on a constant currency basis).
• Q3 2025 net income significantly increased to $48 million ($0.17 per diluted share) from $17 million ($0.06 per diluted share) in Q3 2024.
• Q3 2025 Adjusted EBITDA increased 12.2% to $164 million (11.2% on a constant currency basis).
• Q3 2025 Adjusted EPS increased by $0.09 to $0.26.
• Year-to-date 2025 net revenues increased 6.2% to $860 million.
• Year-to-date 2025 Adjusted EBITDA increased 10.4% to $437 million.
• Year-to-date 2025 Adjusted EPS increased by $0.11 to $0.60.
• The 2025 Adjusted EBITDA growth range was raised to 6.75% 7.75% (from 6.00% 7.50%).
• The 2025 Adjusted EPS range was raised to $0.81 $0.86 (from $0.75 $0.82).
• Interest expense outlook for 2025 improved to $154 million to $158 million (from $155 million to $165 million).
• Tax rate applicable to Adjusted Net Income outlook for 2025 improved to 29.00% to 31.00% (from 31.5% to 33.5%).
• Net Leverage Ratio improved to 3.3x as of September 30, 2025, moving closer to the long-term goal of 2.0x to 3.0x.
• Achieved a contractual net leverage target, triggering a 25 basis point reduction in the interest rate on its First Lien Term Loan facility.
• Amended its First Lien Term Loan facility, reducing the interest rate spread over SOFR from 300 basis points to 250 basis points, and concurrently repaid $75 million of the facility.
• Sterigenics delivered strong Q3 2025 results with net revenues up 9.8% to $193 million (8.4% constant currency) and segment income up 11.6% to $107 million.
• Nordion net revenues increased 22.4% to $63 million (23.6% constant currency) and segment income increased 19.9% to $38 million in Q3 2025.
• Nelson Labs segment income increased 1.9% to $19 million in Q3 2025, with segment income margin expansion due to volume and mix improvements, lab optimization, and favorable pricing.

Negatives

• Nelson Labs net revenues decreased 5.0% to $56 million (6.4% on a constant currency basis) in Q3 2025.
• Nelson Labs year-to-date net revenues decreased 5.8% to $165 million (6.4% on a constant currency basis).
• The decline in Nelson Labs' revenues was primarily driven by a decrease in expert advisory services revenues.
• Nordion's segment income margin decreased as a result of product mix.

Risks

• A disruption in the availability or supply of, or increases in the price of, EO, Co-60 or other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia.
• Fluctuations in foreign currency exchange rates.
• Evolving changes in environmental, health and safety regulations or preferences, and general economic, social and business conditions.
• Health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60.
• The impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from facilities in California, Georgia, Illinois and New Mexico and the possibility that additional claims will be made in the future.
• The ability to satisfy the conditions for settlement of the EO claims related to the former facility in Willowbrook, Illinois.
• Allegations of failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm.
• Compliance with extensive regulatory requirements, the related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals.
• Adverse changes in industry trends and competition.
• Market conditions and changes, including inflationary trends and the impact of tariffs, that impact long-term supply contracts with variable price clauses and increase cost of revenues.
• Business continuity hazards, including supply chain disruptions, the impact of the U.S. federal government shutdown, and other risks associated with operations.
• The risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions.
• The ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for leased facilities.
• The ability to attract and retain qualified employees.
• Severe health events or environmental events.
• Cybersecurity incidents, unauthorized data disclosures, and dependence on information technology systems.
• An inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into the business successfully.
• The ability to maintain effective internal control over financial reporting.
• Reliance on intellectual property to maintain competitive position and the risk of claims from third parties for infringement or misappropriation.
• The ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts.
• The ability to generate profitability in future periods.
• Impairment charges on goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives.
• The effects of unionization efforts and labor regulations in countries in which the company operates.
• Adverse changes to tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of operations.
• Significant leverage and how this could adversely affect the ability to raise additional capital, limit the ability to react to challenges, limit flexibility in operating the business through debt agreement restrictions, and/or prevent meeting obligations under existing and future indebtedness agreements.

Future Outlook

The company reaffirmed its 2025 net revenues growth outlook in the range of 4.5% to 6.0% on a constant currency basis, with foreign currency expected to contribute approximately 25 basis points. The Adjusted EBITDA growth range for 2025 was raised to 6.75% to 7.75% (from 6.00% to 7.50%), also with an expected 25 basis point contribution from foreign currency. The interest expense outlook improved to $154 million to $158 million, and the tax rate applicable to Adjusted Net Income improved to 29.00% to 31.00%. The Adjusted EPS range was raised to $0.81 to $0.86. Capital expenditures for 2025 are now expected to be in the range of $125 million to $135 million, a reduction from the previous outlook.

Management Comments

• "Today, we reported strong top-line revenue growth and double-digit Adjusted EBITDA growth, with approximately 150 basis points of margin expansion."
• "Sterigenics continued its strong volume performance, Nordion achieved double-digit revenue and segment income growth, and Nelson Labs continued to expand segment income margins."
• "Based on our year-to-date performance and good visibility into the remainder of this year, we are reaffirming our 2025 revenue outlook and raising our Adjusted EBITDA outlook."

Industry Context

Sotera Health operates in the mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry. The strong performance in sterilization (Sterigenics) and Nordion (Cobalt-60 supply) suggests robust and sustained demand in the medical device and broader healthcare sectors, which rely heavily on these services for product safety and regulatory compliance. The overall positive results reflect a healthy demand environment for essential healthcare infrastructure services, indicating resilience and strategic positioning within its specialized markets. While Nelson Labs experienced a revenue decline in expert advisory services, the segment's improved income margins suggest effective operational management despite specific market shifts.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against global industry standards.
• The company's improved Net Leverage Ratio to 3.3x, moving closer to its long-term goal of 2.0x to 3.0x, indicates a strengthening financial position relative to its own targets, which is generally viewed favorably within the industry for debt management.

Legal Proceedings

• Previously disclosed settlement of approximately $31 million related to ethylene oxide (EO) claims against Sterigenics.
• Pending settlement of $34 million related to ethylene oxide (EO) claims against Sterigenics.
• Cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to a term sheet entered into on April 3, 2025.
• Cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to a term sheet entered into on July 23, 2025.
• Ongoing risk of current and future legal proceedings and liability claims, including litigation related to the use, emissions, and releases of EO from facilities in California, Georgia, Illinois, and New Mexico, and the possibility that additional claims will be made.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased outlook, improved profitability, and reduced leverage, potentially leading to increased share value.
• Creditors: Positive impact due to reduced total debt, improved Net Leverage Ratio, and reduced interest expense, indicating lower credit risk.
• Customers: Continued provision of mission-critical sterilization and lab testing services, with strong performance in Sterigenics and Nordion suggesting reliable service delivery.
• Employees: Continued operational strength and growth across segments, though no specific employee-related announcements were made.
• Regulatory Authorities: Ongoing management of ethylene oxide (EO) claims and compliance with environmental, health, and safety regulations remain a focus.

Next Steps

• Conference call on November 4, 2025, at 9:00 a.m. Eastern Time to discuss financial results.
• Wolfe Healthcare Conference on November 17, 2025, at 1:20 p.m. Eastern Time.
• Jefferies London Healthcare Conference on November 19, 2025, at 8:30 a.m. Greenwich Mean Time.
• Citi Global Healthcare Conference on December 2, 2025, at 9:45 a.m. Eastern Time.
• Piper Sandler 36th Annual Healthcare Conference on December 3, 2025, at 11:00 a.m. Eastern Time.

Key Dates

Recommendation

The company delivered robust third-quarter results, exceeding expectations with double-digit growth in Adjusted EBITDA and a significant increase in net income. The upward revision of the full-year Adjusted EBITDA and Adjusted EPS outlook, coupled with a notable improvement in the Net Leverage Ratio and a reduction in interest expense, demonstrates strong operational execution and prudent financial management. While Nelson Labs experienced a revenue decline in advisory services, the overall strength across the Sterigenics and Nordion segments, which are core to the company's mission-critical services, provides a solid foundation for continued growth. The proactive management of debt and the positive outlook suggest a strong investment opportunity.

Keywords

Sotera Health, SHC, sterilization solutions, lab testing, advisory services, healthcare industry, financial results, Q3 2025, Adjusted EBITDA, Adjusted EPS, net revenues, Sterigenics, Nordion, Nelson Labs, ethylene oxide, EO claims, debt reduction, leverage ratio